logo
logo

Octave Bioscience Secures $32 Million Series B Financing

Dec 17, 2020•almost 5 years ago

Amount Raised

$32 Million

Round Type

series b

Menlo ParkBiotechnology

Description

Octave Bioscience, the developer of a fully integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases, today announced the completion of a $32 million Series B financing. Northpond Ventures led the investment round with participation by Deerfield Management and Casdin Capital. All previous investors participated in the financing round, including the Blue Venture Fund, Echo Health Ventures, Section 32 and several private investors. This financing will allow the company to complete development of its novel measurement and management products and services, further expand clinical data, initiate early commercial activities and begin to serve neurologists, MS patients and health plans.

Company Information

Company

Octave Bioscience

Location

Menlo Park, California, United States

About

Octave® Bioscience Inc. is a commercial-stage precision medicine company transforming care for Multiple Sclerosis and other neurodegenerative diseases. Its Precision Care Solution is the first industry platform to objectively measure disease activity, progression, and severity through tools such as the Octave MSDA Test — the only multivariate blood test for MS — alongside advanced MRI analytics, specialized protocols, and a clinical care program that connects patients with MS-certified nurse partners in real time. By integrating and analyzing diverse biological and contextual data layers, Octave delivers holistic, longitudinal patient insights and population-level intelligence, addressing critical unmet needs for patients, providers, pharma, and payers. Currently, the company is collaborating with leading clinics, payers, and pharmaceutical partners nationwide to advance this new paradigm of care.

Related People

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech